Author:
Wu Hsiang-Ling,Wu Yu-Ming,Chen Jui-Tai,Chang Kuang-Yi,Cherng Yih-Giun,Lin Shih-Pin,Tsou Mei-Yung,Tai Ying-Hsuan
Abstract
Abstract
Clinical and pathological predictors have proved to be insufficient in identifying high-risk patients who develop cancer recurrence after tumour resection. We aimed to compare the prognostic ability of various inflammation markers in patients undergoing surgical resection of lung cancer. We consecutively included 2,066 patients with stage I–III non-small-cell lung cancer undergoing surgical resection at the center between 2005 and 2015. We evaluated prognostic nutritional index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio along with their perioperative changes. We conducted stepwise backward variable elimination and internal validation to compare the selected markers’ predictive performance for postoperative recurrence-free survival and overall survival. Preoperative neutrophil-to-lymphocyte ratio independently predicts recurrence-free survival (HR: 1.267, 95% CI 1.064–1.509, p = 0.0079, on base-2 logarithmic scale) and overall survival (HR: 1.357, 95% CI 1.070–1.721, p = 0.0117, on base-2 logarithmic scale). The cut-off value is 2.3 for predicting both recurrence (sensitivity: 46.1% and specificity: 66.7%) and mortality (sensitivity: 84.2% and specificity: 40.4%). Advanced cancer stage, poor tumour differentiation, and presence of perineural infiltration were significantly correlated with higher preoperative neutrophil-to-lymphocyte ratio. We concluded that preoperative neutrophil-to-lymphocyte ratio is superior to prognostic nutritional index and platelet-to-lymphocyte ratio in predicting postoperative recurrence and mortality of patients undergoing surgical resection of non-small-cell lung cancer.
Funder
Ministry of Science and Technology, Taiwan
Shuang Ho Hospital, Taipei Medical University
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. World Health Organization, International Agency for Research on Cancer. GLOBOCAN: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed July 25, 2020.
2. National Comprehensive Cancer Network (NCCN) Guidelines for Treatment of Cancer by Site 2019. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed on July 25, 2020.
3. Lou, F. et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J. Thorac. Cardiovasc. Surg. 145, 75–81 (2013).
4. Lu, Y., Jiang, J. & Ren, C. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: a meta-analysis. PLoS ONE 15, e0230979 (2020).
5. Li, D., Yuan, X., Liu, J., Li, C. & Li, W. Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis. J. Thorac. Dis. 10, 5298–5307 (2018).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献